<DOC>
	<DOCNO>NCT02261636</DOCNO>
	<brief_summary>For induction remission maintenance remission , different dos treatment duration use practice . The aim study assess mesalazine use clinical practice , dose long difference impact patient disease state work productivity .</brief_summary>
	<brief_title>Induction Maintenance Remission With Pentasa Ulcerative Colitis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients mild moderate active ulcerative colitis disease extension beyond rectum ( â‰¥ 10 cm ) receive oral Pentasa treatment ( Compact sachet and/or tablet ) treatment current active episode oral Pentasa maintenance treatment induction remission treatment initiate dose escalation . Treatment combine Pentasa enema ( 1g/100ml ) allow . Informed consent Patients receive treatment one following : locally act steroid ( e.g . budesonide , beclomethasone ) , systemic steroid , immunosuppressant ( e.g . thiopurines ) , biologicals ( e.g . antiTumor Necrosis Factoralpha )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>